Advertisement

EKG PARAMETERS IN PREDICTING SURVIVALS IN PULMONARY ARTERIAL HYPERTENSION

      TOPIC: Pulmonary Vascular Disease
      TYPE: Original Investigations
      PURPOSE: EKG parameters are ones of the predictors for prognosis of the patients with pulmonary arterial hypertension (PAH).
      METHODS: We analyzed the imaging and EKG variables obtained at baseline in 4 PAH clinical trials: SERAPHIN, BREATHE-1, CHEST-2, and PATENT-2. The outcome of the analysis was mortality at the time to event of each individual trial. We selected only the significant EKG variables (p-value<0.05) to be aggregated across the clinical trials using Stouffer’s method, weighed by their ‘N’ in the clinical trials.
      RESULTS: Collective data from 1,579 patients were available at baseline with 10 EKG variables. Out of the 10, only 4 variables were still significant (p-value<0.05) after the aggregation of p-values: 1) Non-sinus rhythms: HR=6.11 [1.36; 27.33], aggregated p-value=0.0180, N=213; 2) Mean ventricular rate (beat/min): HR=1.04 [1.02; 1.07], aggregated p-value=0.0011, N=393; 3) QRS interval (ms): HR=0.99 [0.95; 1.03], aggregated p-value=0.0242, N=948; and 4) Atrial or ventricular extrasystole: HR=0.35 [0.04; 3.33], aggregated p-value=0.0041, N=231. The most predictive variable to mortality were non-sinus rhythm followed by the mean ventricular rate, while the presence of atrial or ventricular extrasystole is protective.
      CONCLUSIONS: To our knowledge, this is the largest aggregated attempt to analyze EKG parameters in predicting survivals. This analysis will be used to select features for the derivation of machine-learned PAH patient risk stratification models
      CLINICAL IMPLICATIONS: Our long-term goal is to generate a comprehensive personalized risk assessment tool from the data-driven variable selections to aid clinical decisions.
      DISCLOSURES: No relevant relationships by James Antaki, source=Web Response
      Grants relationship with Actelion Please note: 2019-2021 Added 04/29/2021 by Raymond Benza, source=Web Response, value=Grant/Research Support
      Grants relationship with Bayer AG Please note: 2019-2021 Added 04/29/2021 by Raymond Benza, source=Web Response, value=Grant/Research Support
      Grants relationship with Bellerophon Please note: 2019-2021 Added 04/29/2021 by Raymond Benza, source=Web Response, value=Grant/Research Support
      Grants relationship with EIGER Please note: 2019-2021 Added 04/29/2021 by Raymond Benza, source=Web Response, value=Grant/Research Support
      No relevant relationships by Allen Everett, source=Web Response
      Advisory Committee Member relationship with Bayer Please note: 2016-2019 Added 04/30/2021 by Manreet Kanwar, source=Web Response, value=Consulting fee
      No relevant relationships by Jidapa Kraisangka, source=Web Response
      No relevant relationships by Shili Lin, source=Web Response
      No relevant relationships by Zilu Liu, source=Web Response
      No relevant relationships by Faezeh Movahedi, source=Web Response
      Advisory Committee Member relationship with Blue Spark Technologies Please note: 2020-Present Added 04/16/2021 by Adam Perer, source=Web Response, value=Consulting fee
      Consultant relationship with Johnson & Johnson Please note: 2021-Present Added 04/16/2021 by Adam Perer, source=Web Response, value=Consulting fee
      No relevant relationships by Jacqueline Scott, source=Web Response